The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1648
April 18, 2022
View Complete Issue         Table of Contents 2019 
A Drug-Eluting Contact Lens for Allergic Conjunctivitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Drug-Eluting Contact Lens for Allergic Conjunctivitis
April 18, 2022 (Issue: 1648)
The FDA has approved Acuvue Theravision with Ketotifen (Johnson & Johnson Vision Care), a daily-wear, disposable, vision-correcting soft contact lens that releases the H1-antihistamine ketotifen, for prevention of ocular itch due to allergic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A Drug-Eluting Contact Lens for Allergic Conjunctivitis
Article code: 1648c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.